EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis

Tracey G Simon, Robert M Wilechansky, Stefania Stoyanova, Alessandra Grossman, Laura E Dichtel, Georg M Lauer, Karen K Miller, Yujin Hoshida, Kathleen E Corey, Rohit Loomba, Raymond T Chung, Andrew T Chan

JAMA · 19.03.2024 · 331 (11) · 920

DOI: 10.1001/jama.2024.1215 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JAMA, erschienen am 19.03.2024. Verfasst von Tracey G Simon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Epidemiology Unit (CTEU), Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Aspirin, Fatty Liver, Liver. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Aspirin may reduce severity of metabolic dysfunction–associated steatotic liver disease (MASLD) and lower the incidence of end-stage liver disease and hepatocellular carcinoma, in patients with MASLD. However, the effect of aspirin on MASLD is unknown.

Objective

To test whether low-dose aspirin reduces liver fat content, compared with placebo, in adults with MASLD. Design, Setting, and Participants This 6-month, phase 2, randomized, double-blind, placebo-controlled clinical trial was conducted at a single hospital in Boston, Massachusetts. Participants were aged 18 to 70 years with established MASLD without cirrhosis. Enrollment occurred between August 20, 2019, and July 19, 2022, with final follow-up on February 23, 2023.

Interventions

Participants were randomized (1:1) to receive either once-daily aspirin, 81 mg (n = 40) or identical placebo pills (n = 40) for 6 months. Main Outcomes and Measures The primary end point was mean absolute change in hepatic fat content, measured by proton magnetic resonance spectroscopy (MRS) at 6-month follow-up. The 4 key secondary outcomes included mean percentage change in hepatic fat content by MRS, the proportion achieving at least 30% reduction in hepatic fat, and the mean absolute and relative reductions in hepatic fat content, measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF). Analyses adjusted for the baseline value of the corresponding outcome. Minimal clinically important differences for study outcomes were not prespecified.

Results

Among 80 randomized participants (mean age, 48 years; 44 [55%] women; mean hepatic fat content, 35% [indicating moderate steatosis]), 71 (89%) completed 6-month follow-up. The mean absolute change in hepatic fat content by MRS was −6.6% with aspirin vs 3.6% with placebo (difference, −10.2% [95% CI, −27.7% to −2.6%]; P = .009). Compared with placebo, aspirin treatment significantly reduced relative hepatic fat content (−8.8 vs 30.0 percentage points; mean difference, −38.8 percentage points [95% CI, −66.7 to −10.8]; P = .007), increased the proportion of patients with 30% or greater relative reduction in hepatic fat (42.5% vs 12.5%; mean difference, 30.0% [95% CI, 11.6% to 48.4%]; P = .006), reduced absolute hepatic fat content by MRI-PDFF (−2.7% vs 0.9%; mean difference, −3.7% [95% CI, −6.1% to −1.2%]; P = .004]), and reduced relative hepatic fat content by MRI-PDFF (−11.7 vs 15.7 percentage points; mean difference, −27.3 percentage points [95% CI, −45.2 to −9.4]; P = .003). Thirteen participants (32.5%) in each group experienced an adverse event, most commonly upper respiratory tract infections (10.0% in each group) or arthralgias (5.0% for aspirin vs 7.5% for placebo). One participant randomized to aspirin (2.5%) experienced drug-related heartburn. Conclusions and Relevance In this preliminary randomized clinical trial of patients with MASLD, 6 months of daily low-dose aspirin significantly reduced hepatic fat quantity compared with placebo. Further study in a larger sample size is necessary to confirm these findings. Trial Registration ClinicalTrials.gov Identifier: NCT04031729

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory AgentsAspirinFatty LiverLiverAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultCarcinoma, HepatocellularDouble-Blind MethodEnd Stage Liver DiseaseFollow-Up StudiesLiver CirrhosisLiver NeoplasmsProton Magnetic Resonance Spectroscopy

Substanzen

Anti-Inflammatory AgentsAspirin

Autor:innen und Institutionen

  • Clinical and Translational Epidemiology Unit (CTEU), Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston, Massachusetts.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Massachusetts General Hospital, Boston.
  • Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston.
  • Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NCI NIH HHS

Zitieren

APA

Simon, T. G., Wilechansky, R. M., Stoyanova, S., Grossman, A., Dichtel, L. E., Lauer, G. M., Miller, K. K., Hoshida, Y., Corey, K. E., Loomba, R., Chung, R. T., & Chan, A. T. (2024). Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis. JAMA, 331(11), 920. https://doi.org/10.1001/jama.2024.1215

Vancouver

Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, et al. Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis. JAMA. 2024;331(11):920. doi:10.1001/jama.2024.1215

BibTeX
@article{Simon2024,
  author = {Simon, Tracey G and Wilechansky, Robert M and Stoyanova, Stefania and Grossman, Alessandra and Dichtel, Laura E and Lauer, Georg M and Miller, Karen K and Hoshida, Yujin and Corey, Kathleen E and Loomba, Rohit and Chung, Raymond T and Chan, Andrew T},
  title = {Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {11},
  pages = {920},
  doi = {10.1001/jama.2024.1215}
}
Kostenlos starten →